Davide C.
- Country
- Italy
- Department
- Department of Medical and Surgical Sciences
Research Overview
- Phase 3 Trial of Octreotide Subcutaneous Depot vs. Octreotide LAR or Lanreotide ATG in Unresectable/Metastatic GEP-NET Patients
- Efficacy and Safety Evaluation of Lutetium (177Lu) Oxodotreotide in Advanced GEP-NETs with High Proliferation: A Phase III Randomized Study
- Evaluation of Cabozantinib and Lanreotide Combination in Gastroenteropancreatic and Thoracic Neuroendocrine Tumors: A Phase II Clinical Trial
Data & Insights
Has run more than one trial at 57 of 116 partner sites.
Specializations
Neuroendocrine Cancer
This investigator specializes in treating various forms of neuroendocrine tumors, with particular emphasis on gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and pulmonary large-cell neuroendocrine carcinoma (LCNEC).
- Advanced GEP-NETs
- Thoracic NETs
- Metastatic LCNEC
The investigator's work encompasses both well-differentiated and high-proliferation rate tumors.
Therapeutic Approaches
The investigator focuses on innovative treatment combinations involving targeted therapies and immunotherapy for neuroendocrine cancers.
- Somatostatin Analog Therapy
- Immunotherapy Combinations
- Multi-targeted Treatment Approaches
Their expertise includes both first-line treatments and maintenance therapy strategies.
Clinical Interests
The investigator's clinical focus encompasses advanced stage cancers and metastatic disease, with particular attention to tumor grade differentiation.
- Treatment-naïve Patients
- High-grade Tumors
- Unresectable Neoplasms
Their work includes evaluation of novel therapeutic combinations for improved patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.